



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

<b>Reagent:</b>	Jurkat Tat+ Cells
<b>Catalog Number:</b>	1399
<b>Lot Number:</b>	160144
<b>Release Category:</b>	D
<b>Provided:</b>	1 mL of cells Post thaw cell count = $5.6 \times 10^6$ cells/mL Post thaw cell viability = 90% Cell viability increased to 97% after 4 days in culture.
<b>Cell Type:</b>	Human T-lymphocytic cell line.
<b>Propagation Medium:</b>	RPMI 1640, 90%; fetal bovine serum, 10%; G418, 800 $\mu$ g/mL.
<b>Freeze Medium:</b>	Fetal bovine serum, 90%; DMSO, 10%.
<b>Growth Characteristics:</b>	Maintain cells at approximately $5 \times 10^5$ cells/mL. Doubling time is 25 hours. Passage twice weekly. Jurkat Tat+ Cells grow in suspension both singly and as clumps.
<b>Morphology:</b>	Lymphocytic; very similar to parent cell line.
<b>Sterility:</b>	Negative for mycoplasma, bacteria and fungi
<b>Description:</b>	A Jurkat cell line that stably expresses HIV-1 tat.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**Special Characteristics:** A BK virus plasmid expression vector containing HIV-1 *tat* cDNA and a neomycin resistance selection marker was used to transfect Jurkat cells. It is unclear whether Tat is secreted into the culture medium. These cells are CD4+ and are easily infected with HIV-1.

**Recommended Storage:** Keep the reagent in liquid nitrogen

**Contributor:** Drs. Antonella Caputo, William Haseltine, and Joseph Sodroski.

**References:** Caputo, A., Sodroski, J. G., & Haseltine, W. A. (1990). Constitutive expression of HIV-1 *tat* protein in human Jurkat T cells using a BK virus vector. *J Acquir Immune Defic Syndr*, 3(4), 372-379. [PUBMED](#)

**NOTE:** Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Jurkat *tat*+ Cells from Drs. Antonella Caputo, William Haseltine, and Joseph Sodroski." Also include the reference cited above in any publications.

**This and other stable cell lines expressing *tat* III is described in US Patent #4,981,790. Requests from commercial organizations must be directed to both Dr. Joseph Sodroski, Division of Human Retrovirology, JFB824, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA, 02115, and the Director, Office of Technology Transfer, Dana-Farber Cancer Institute, 44 Binney Street, Suite L660, Boston, MA 02115.**

**Last Updated** March 19, 2019

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.